Live Breaking News & Updates on Hoyer Millar|Page 1

Stay updated with breaking news from Hoyer millar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ixaka appoints Christian Hoyer Millar as a Non-Executive Director


Posted on
389
Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, today announces that Christian Hoyer Millar has joined the Company’s Board as a Non-Executive Director.
Christian Hoyer Millar has extensive corporate experience across life sciences and biotech. He is the Founder and a current Director of both Chronos Therapeutics Limited and Sibelius Limited. Previously, up until 2020 Christian was also the Founder, Director and CEO of Oxford Biodynamics, an Oxford University spin out and world leader in 3D genomics, which went public on the AIM market in 2017.
Christian started his career at the Boston Consulting Group, working in both Europe and the US. Christian then moved to the UK holding company of the Dutch conglomerate Hoogovens, where he acted as Director for numerous subsidiaries. He moved on to become Vice President of Fox Pitt Kel ....

France General , United Kingdom , United States , City Of , Joe Dupere , Christian Hoyer Millar , Fox Pitt Kelton , Chronos Therapeutics , Lincoln College , Company Board , Boston Consulting Group , Ixaka Ltd , Oxford University , Hoyer Millar , Chronos Therapeutics Limited , Oxford Biodynamics , Vice President , Non Executive Director , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , கிறிஸ்துவர் ஹோயர் மில்லர் , நரி குழி கேள்டோன் , குரோனோஸ் சிகிச்சை , லிங்கன் கல்லூரி ,

Investegate |Oxford BioDynamics Announcements | Oxford BioDynamics: Directorate Change


About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch™, which can
build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in
more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome know ....

United Kingdom , City Of , United States , Alexandre Akoulitchev , Paul Stockdale , Edward Mansfield John , Tanabe Pharma , Christian Hoyer Millar , Jon Burrows , Aroul Ramadass , London Stock Exchange , Oxford Biodynamics Plc , Oxford Biodynamics , Executive Director , Hoyer Millar , Agnes Stephens , Biodynamics Plc , Mayo Clinic , Massachusetts General Hospital , Mitsubishi Tanabe , London Stock , Oxford Biodynamic , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஒன்றுபட்டது மாநிலங்களில் , பால் ஸ்டாக்‌டேல் ,